Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells

BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are elevated in the circulation of patients with glioblastoma (GBM), present in tumor tissue, and associated with poor prognosis. While low-dose chemotherapy reduces MDSCs in preclinical models, the use of this strategy to reduce MDSCs in GBM pati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JCI Insight
Autors principals: Peereboom, David M., Alban, Tyler J., Grabowski, Matthew M., Alvarado, Alvaro G., Otvos, Balint, Bayik, Defne, Roversi, Gustavo, McGraw, Mary, Huang, Pengjing, Mohammadi, Alireza M., Kornblum, Harley I., Radivoyevitch, Tomas, Ahluwalia, Manmeet S., Vogelbaum, Michael A., Lathia, Justin D.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2019
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948860/
https://ncbi.nlm.nih.gov/pubmed/31600167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.130748
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars